COVID-19 Pandemic Impact: Global R&D Spend For AI in Healthcare and Pharmaceuticals Will Increase US$1.5 Billion By 2025

ABI Research whitepaper identifies the short-and long-term impacts the global pandemic will have on Artificial Intelligence and Machine Learning

Oyster Bay, New York - 15 Apr 2020

The Coronavirus outbreak has proven that healthcare institutions can no longer ignore the role of Artificial Intelligence (AI) in their daily workflow. AI spending in the healthcare and pharmaceutical industries is expected to increase from US$463 million in 2019 to more than US$2 billion over the next 5 years, states global tech market advisory firm, ABI Research.

“Artificial Intelligence is playing a key role in responding to the pandemic,” says Lian Jye Su, Principal Analyst at ABI Research. Several companies, including Alibaba, YITU, Graphen, and Google DeepMind, are already developing AI tools to help detect the virus, diagnose its evolution, track its geographical footprint, project its future, and even predict its potential protein structure to find a vaccine for it.

Aside from viral detection, AI will be adopted in the field of bioinformatics, where the Ribonucleic Acid (RNA) sequence of COVID-19 can be thoroughly analyzed to develop the right antiviral drugs. “Now, no single drug can combat the virus effectively. In order to get ahead of the ever-evolving virus and to save as many lives as possible, new drug discovery, development, and testing processes need to be set up, as the conventional method is no longer suitable,” Su explains. Tools from established companies like Google DeepMind, startups like Graphen, and AI chipsets from vendors like NVIDIA and Intel will help accelerate the speed of drug discovery, development, and testing, allowing pharmaceutical companies and healthcare authorities to combat the pandemic.

Pharmaceutical companies and healthcare authorities will take lessons from the current chaotic situation, and anticipate universal programs and frameworks to better manage pandemic situations, predict the emergence and the spread of viruses, and, most importantly, find a cure for them in a timely fashion. The situation will encourage healthcare agencies, pharmaceutical vendors, and webscale companies to enhance their Research and Development (R&D) investments in AI as a core technology for enabling these initiatives.

Global R&D expenditures for the pharmaceutical industry are estimated to be between US$180 billion and US$195 billion in 2022. AI spending in the healthcare and pharmaceutical industries is expected to increase from US$463 million in 2019 to more than US$2 billion by 2025. “The pharmaceutical industry is a significant market that AI hardware and software vendors should target,” Su advises.

For a clearer picture of the current and future ramifications of COVID-19 across technologies and industries, download the whitepaper Taking Stock of COVID-19: The Short- and Long-Term Ramifications on Technology and End Markets.

 

About ABI Research

ABI Research provides strategic guidance to visionaries, delivering actionable intelligence on the transformative technologies that are dramatically reshaping industries, economies, and workforces across the world. ABI Research's global team of analysts publish groundbreaking studies often years ahead of other technology advisory firms, empowering our clients to stay ahead of their markets and their competitors.

ABI Research提供开创性的研究和战略指导,帮助客户了解日新月异的技术。 自1990年以来,我们已与全球数百个领先的技术品牌,尖端公司,具有远见的政府机构以及创新的贸易团体建立了合作关系。 我们帮助客户创造真实的业务成果。

For more information about ABI Research's services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific or visit www.abiresearch.com.

Contact ABI Research

Media: Interview an Analyst

Media Contacts

Americas: +1.516.624.2542
Europe: +44.(0).203.326.0142
Asia: +65 6950.5670